News

2006

Medgraph awarded Phase II SBIR funding!

Good news came in early October when we recieved word that Medgraph won Phase II SBIR funding for development of their Glucose Monitoring System. Co-written with AZtech and including input from the T2RERC, Medgraph submitted the Phase II proposal in April and had been eagerly awaiting the results.  Congratulations on a job well done to Medgraph and all those who put time and effort into writing and editing the proposal.

The abstract for this project can be seen below. For more information on this project or how to write and submit your winning SBIR proposal, visit our “Contact Us” page.

Abstract
Medgraph, Inc. (MGI) is developing a Glucose Monitoring System (GMS) that will be accessible to people with vision and hearing impairments. The GMS will work in conjunction with a Life Improvement Portal (LIP) to collect, store, analyze, and track glucose readings for people with diabetes. The GMS will connect, via a standard phone line, to the LIP to ensure that the person with diabetes is immediately notified of low, normal, and high glucose thresholds that have been established by their physician. Physicians will be able to immediately access this information via the central server, helping to avoid complications from fluctuating glucose levels. The LIP uploads glucometer information at the push of a button or at predetermined intervals throughout the day into the secure central server. Once transmitted, data is analyzed for emergency indicators, and priority information is reported back to both the diabetic user via feedback from the LIP. All aggregated data can then be viewed by the person with diabetes, an approved caregiver, or a physician in graphical formats via a secure website that is accessible to W3C standards. 

Summary of Anticipated Results and Potential Commercial Applications
MGI used Phase I SBIR funds to successfully prove the feasibility of the Life Improvement Portal (LIP) Glucose Monitoring System (GMS). During Phase II, MGI intends to refine and ready the pre-production prototype for Phase III commercialization by incorporating additional consumer input into its design; further developing the GMS capabilities to include voice output; and test the effectiveness and consumer satisfaction levels via clinical trials. MGI will also use Phase II funding to further discussions with existing glucometer manufacturers, in order to finalize a manufacturing agreement with a partner organization. 

MGI expects that this Phase II SBIR work, particularly the clinical trial data combined with input from professionals, will significantly advance knowledge regarding the needs of people with visual and hearing impairments in relation to health monitoring devices. In order to disseminate this newfound information, Dr. Machiko Tomita, who will run the Phase II clinical trials, will present a paper at a Nationally recognized disability conference. This activity will ensure that the Phase II work not only benefits MGI and the development of the LIP, but will also create value for others interested in developing or researching similar products to enhance the quality of life for people with disabilities. 

[ back to news page ]